As executive vice president of drug development for the Americas
Mahmoud Ghazzi has joined Daiichi Sankyo Pharma Development (DSPD) as its new executive vice president of drug development for the Americas.
DSPD, headquartered in Edison, NJ, runs clinical trials throughout the region and Ghazzi will work closely with the global development regional heads in Asia, Japan and Europe to ensure delivery of clinical development programmes.
He will oversee critical regional functions such as clinical development, regulatory affairs, translational medicine and clinical pharmacology and clinical safety and pharmacovigilance. He also be co-chairman of the Daiichi Sankyo Global Clinical Committee, which ensures that all programmes meet the highest standards.
Prior to joining DSPD, Ghazzi served in roles of increasing responsibility at GlaxoSmithKline (GSK) and Pfizer where he developed and managed clinical trials for cardiovascular, metabolism, obesity and diabetes drugs.